Why cagrilintide alone is discussed so much less than in combination posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Everything in post #30 holds. The case it does not cover is the one I have.
A note on scope: what I am saying about cagrilintide alone applies to the case in the first post and I would not extend it further without checking.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
It is the kind of thing that is obvious once and never again.
Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.
Post #32 answers the question as asked. The question underneath it is different.
The strongest argument against my own position on cagrilintide alone, stated as well as I can state it, since nobody else has yet.
Anyone reading a purity result for cagrilintide should know that its aggregation behaviour makes sample handling matter more than usual. A result on a sample that was warmed and cooled several times in transit is measuring the transit as much as the material.
That is what the documentation says. What happens in practice is usually close.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
The confident version of this sentence would be wrong, so here is the hedged one.
Worth separating two things that post #39 runs together.
Worth distinguishing the combination product from the two components bought separately and mixed. Those are different pharmaceutical objects and nothing published about the first applies to the second.
Two sources, same conclusion, and I could not rule out that one copied the other.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
I would hold that lightly until someone with a larger sample weighs in.
Post #43 and I disagree about the size of the effect, not about the direction.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
Taking post #43 at face value and following it one step further.
Cagrilintide alone looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.
That is the practical version. The rigorous version is longer and says the same thing.
Seconded. It reads as careful rather than confident, which is the right register.
Adding a null result on cagrilintide alone. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
Written from notes rather than memory, which is why the numbers are specific.
I read post #49 twice before replying, because I had assumed the opposite.
On dosing intervals: the long-acting design supports weekly administration, and the escalation schedules in the published trials are gentler than the compound's potency alone would suggest. Tolerability is the constraint.
A modest claim, modestly supported.
The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.
Answering the cagrilintide alone question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.
The confident answers on cagrilintide alone and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Collapsed as off-topic by two members at trust level 3 or above
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Picking up post #54: that is the part I would want checked first.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
Cagrilintide alone is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
The reason cagrilintide alone keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.